Aditxt (NASDAQ:ADTX) Major Shareholder Buys $24,060.96 in Stock

Aditxt, Inc. (NASDAQ:ADTX) major shareholder Financial Lp Hrt purchased 72,912 shares of the stock in a transaction dated Tuesday, April 21st. The stock was acquired at an average price of $0.33 per share, for a total transaction of $24,060.96. Following the completion of the transaction, the insider directly owned 133,574 shares of the company’s stock, valued at approximately $44,079.42. The trade was a 120.19% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, April 22nd, Financial Lp Hrt sold 11,982 shares of Aditxt stock. The stock was sold at an average price of $0.30, for a total transaction of $3,594.60.

Aditxt Trading Down 6.6%

Shares of NASDAQ ADTX traded down $0.02 during midday trading on Thursday, reaching $0.29. 605,118 shares of the stock were exchanged, compared to its average volume of 849,327. The company has a market capitalization of $261,617.60, a P/E ratio of 0.00 and a beta of 1.74. Aditxt, Inc. has a 52-week low of $0.28 and a 52-week high of $2,495.04. The stock has a 50 day moving average price of $2.14 and a 200-day moving average price of $57.64.

Aditxt (NASDAQ:ADTX) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $11,687.53 EPS for the quarter. Aditxt had a negative net margin of 1,217,927.00% and a negative return on equity of 374.60%.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aditxt in a report on Monday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Aditxt currently has an average rating of “Sell”.

About Aditxt

Aditxt, Inc is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt’s approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.

The company’s product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols.